Osteoporoz u molodykh zhenshchin

Гависова, А. А.; Burduli, Anna; Ol'khovskaya, M. A.

doi:10.14341/osteo2010212-14

Osteopor Bone Dis

2010

DOI: 10.14341/osteo2010212-14

|View full text |Cite

Osteoporoz u molodykh zhenshchin

А. А. Гависова¹,

Anna Burduli²,

M. A. Ol'khovskaya³

Abstract: Pubertal and reproductive stages of woman's life are characterized by sex steroids' predominant action. Osteoporosis and osteopenia can develop in patients with estrogen deficiency (amenorrhoea). DXA scans are used to evaluate bone mineral density (BMD) using T-score. Retrospectively, we examine 234 patients with amenorrhoea. The mean age was 31,80,7 years, the mean duration of amenorrhoea was 6,41,2 years. The highest rate of osteoporosis was determined in patients younger then 30 years with gonadal dysgene… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

2020

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 3 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

On the Unification of Bone Densitometry and Interpretation of Its Results

Низовцова¹,

Morozov²,

Petryaykin³

et al. 2018

Vestn. rentgenol. radiol.

View full text Add to dashboard Cite

The paper gives data on the importance of osteoporosis, existing approaches to its diagnosis, the specific features of a dual-energy X- ray absorption procedure to measure bone density, the determination of main densitometric indicators, such as a T-score and a Z-score, as well as their interpretation, by predicting the probability of bone fractures. It shows the need for population-based studies in Russia to set up a normative bone mineral density base with regard to age- and gender-related differences and other factors influencing the bone structure. The concept of a threshold for intervention is discussed, which determines diagnostic and therapeutic tactics depending on what risk group a patient belongs to. It is noted that the surveys conducted among radiologists have indicated that most specialists are poorly aware of the problem of osteoporosis, its diagnosis, prevention, and treatment.

show abstract

On the Unification of Bone Densitometry and Interpretation of Its Results

Низовцова¹,

Morozov²,

Petryaykin³

et al. 2018

Vestn. rentgenol. radiol.

View full text Add to dashboard Cite

show abstract

Modern methods of prevention and treatment of postmenopausal osteoporosis

Savchenko¹,

Алешкин²,

Афанасьев³

et al. 2018

Med. sov.

View full text Add to dashboard Cite

Osteoporosis constitutes one of the major public health problems in Russia and all over the world; this pathology has showed a tendency toward growth in recent decades. In Russia, osteoporosis was detected in 30.5-33.1% of women aged 50 years and older who underwent densitometry examination, and the incidence of proximal femur fracture for persons over the age of 50 years averages to 105.9 per 100 000. Objective of the study: evaluation of the efficacy of osteo activ in the prevention and treatment of postmenopausal osteoporosis. Materials and methods of the study: 58 postmenopausal patients were examined. In addition to general clinical examination, the concentration of total and ionized Ca, as well as vitamin D in blood plasma were determined in all patients. All examined patients were divided into two groups according to the “case-control” principle: the first group (the main group) included 35 patients who were prescribed osteo activ for the purpose of treating and preventing postmenopausal osteoporosis; the second group (the comparison group) included 23 patients, whose diet was corrected in accordance with the daily requirement of calcium and vitamin D. Results of the study: The study showed a significant increase in the calcium and vitamin D concentration in the blood plasma and a decrease in pain syndrome against the background of the therapy in patients of the main group.

show abstract

Modern principles for the diagnosis and treatment of postmenopausal osteoporosis: a focus on bisphosphonates

Беляева¹,

Мазуров²,

Чудинов³

2020

Medicinskij sovet

View full text Add to dashboard Cite

The article presents the relevance of the problem of postmenopausal osteoporosis (OP) in modern medicine, due to the social and economic consequences of fractures. The pathogenetic mechanisms of its formation are highlighted, indicating that during postmenopausal women amid estrogen deficiency, there is a violation of bone remodeling processes with increased bone resorption and decreased bone formation. Modern recommendations of the pathogenetic therapy of OP are presented, in which it is noted that the drugs of the first choice are drugs of the bisphosphonate class (BF). The ability of BF to suppress the pathological resorption of bone tissue and stimulate bone formation determines their therapeutic effect in OP. One of the drugs of the BF class is alendronate. In the treatment with alendronate, the processes of resorption by osteoclasts are suppressed and the processes of bone metabolism are restored to the premenopausal level, microarchitectural disturbances and bone loss are prevented. It has been demonstrated that the processes of bone metabolism remain stable during prolonged treatment with alendronate for 10 years, while the accumulation of the drug in the bone does not lead to excessive suppression of bone metabolism, but rather remains at the premenopausal level. The data of international and Russian randomized placebo-controlled trials (RCTs) are presented, which indicate the high effectiveness of alendronate at a dose of 70 mg 1 time / week in the treatment of primary OP in postmenopausal women: it had a positive effect on bone mineral density (BMD), reduced pain and, as a result, reduced the restriction of physical activity of patients. Quite good tolerability of the drug was noted, side effects in the treatment group were comparable to those in the placebo group. An analysis of the action of alenadronate shows that it has an aftereffect within a 12-month period after the end of treatment in relation to the BMD of the spine.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Osteoporoz u molodykh zhenshchin

Cited by 3 publications

References 3 publications

On the Unification of Bone Densitometry and Interpretation of Its Results

On the Unification of Bone Densitometry and Interpretation of Its Results

Modern methods of prevention and treatment of postmenopausal osteoporosis

Modern principles for the diagnosis and treatment of postmenopausal osteoporosis: a focus on bisphosphonates

Contact Info

Product

Resources

About